Bipartisan FDA User Fee Reauthorization Is Good Starting Point
Wednesday, April 25, 2012
WASHINGTON, D.C. – Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Tom Harkin (D-Iowa) and Ranking Member Senator Mike Enzi (R-Wyo.) today said the Committee’s markup of FDA user fee reauthorization reflected a strong bipartisan effort.
“Today’s markup of the user fee agreement reauthorizations was an important step,” said Harkin and Enzi. “At a time when Congress has been deeply divided, today’s markup displayed strong bipartisan cooperation.”
Harkin and Enzi noted that this legislation builds upon the current user fee programs, which will expire in September. If new drug and medical device user fee agreements are not authorized before current ones expire, FDA must lay off nearly 2,000 employees. This would derail the premarket review programs, threatening patient access to new therapies, biomedical industry jobs, and America’s global leadership in biomedical innovation.
“In addition to user fees, this bill will reauthorize programs that have helped make medicines safer for millions of children, upgrade FDA’s tools to police the global drug supply chain and ensure that American patients get better access to safe, innovative medical devices and medicines,” said Harkin and Enzi. “This measure will also help reduce the risk of drug shortages.”
# # #
- Harkin: Jobs Report Emphasizes Need to Renew Federal Unemployment Insurance [Chairman]
- GOP Senators Call For Details on Administration Plan to Grant Exemptions from Electronic Health Records Regulations [Ranking Member]
- New Report: 57 Percent of Small Business Owners Support Harkin-Miller Proposal to Raise Minimum Wage to $10.10 [Chairman]
- Bicameral Coalition of Lawmakers Supports FDA’s Proposed Rule to Protect Consumers of Generic Drugs [Chairman]
- Alexander: Obama 10-Year Budget Never Balances, Adds $8 Trillion to Federal Debt [Ranking Member]
- Harkin, Whitehouse, Eshoo, and Lance Applaud Development of Pancreatic Cancer Research Framework [Chairman]